Toronto, July 30, 2025 Spear Bio, a pioneer in ultrasensitive immunoassay technology, has officially launched its next-generation product, SPEAR Ultradetect™, a homogeneous immunoassay solution designed to revolutionize neurodegenerative disease research.
The solution brings unprecedented levels of scalability, sensitivity, specificity, and precision to the measurement of key neurology biomarkers. The initial launch includes four assays targeting critical indicators: neurofilament light (NfL), phosphorylated tau 231 (pTau231), glial fibrillary acidic protein (GFAP), and phosphorylated tau 217 (pTau217).
Spear Bio has partnered with Bio-Techne to support global distribution of the SPEAR Ultradetect platform, further expanding its international footprint in the neurological and broader healthcare market.
Unlike conventional immunoassays that rely on heterogeneous platforms involving solid-surface captures and multiple wash steps, SPEAR Ultradetect is built on Spear Bio’s proprietary homogeneous SPEAR technology. This format allows for wash-free, ultrasensitive detection of biomarkers at attomolar concentrations, drastically reducing the chance of false positives.
At the heart of the SPEAR system is a two-factor authentication mechanism: signals are generated only when antibody pairs remain co-localized on a target protein for extended periods ensuring high specificity in biomarker detection, especially in low-abundance samples from peripheral blood where the blood-brain barrier limits protein visibility.
Fully compatible with a wide range of qPCR instruments used in clinical and academic research labs, SPEAR Ultradetect offers seamless workflow integration and flexibility across assay platforms.
The innovation will be showcased at the Alzheimer’s Association International Conference (AAIC) 2025 on July 27 in Toronto, Canada (Booth #1527), providing a global stage for the technology’s capabilities.
“We’re proud to deliver the first-ever ultrasensitive homogeneous immunoassay strong enough to tackle the challenges of detecting blood-based neurological biomarkers,” said Dr. Feng Xuan, Co-founder and CEO of Spear Bio. “SPEAR Ultradetect will empower researchers worldwide to make new discoveries and accelerate treatments for complex neurological disorders.”
The launch marks a major step forward in biomarker research and could lead to earlier, more accurate diagnoses and breakthroughs in the treatment of neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
